Amgen Inc. vs Mastercard Incorporated: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Mastercard Incorporated across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Mastercard Incorporated, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Mastercard Incorporated is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $32.8B for Mastercard Incorporated, while their respective market capitalizations stand at $228.2B and $495.4B. Both Amgen Inc. and Mastercard Incorporated are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Mastercard Incorporated: Mastercard Incorporated, headquartered in Purchase, New York, connects card issuers, merchants, acquirers and governments in more than 210 countries and territories. In 2025 its network handled about $10.6 trillion in gross dollar volume and 175.5 billion switched transactions. Unlike a bank, Mastercard does not hold consumer loans. It sets network rules, routes and secures payments, and sells data, fraud and cyber services around them. It is listed on the NYSE under the ticker MA and has been led by CEO Michael Miebach since January 2021.

Amgen Inc. and Mastercard Incorporated pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Mastercard Incorporated.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Mastercard Incorporated business model: Mastercard earns money in two ways. Payment network revenue ($19.48 billion in FY2025, about 59% of net revenue) comes from assessments based on gross dollar volume, fees for switching transactions, and higher-yield cross-border fees, reduced by incentives paid to issuers and merchants. Value-added services and solutions (about $13.3 billion, roughly 41%) include fraud and security tools, cyber and threat intelligence, data analytics, consulting, loyalty, open banking and processing. Banks and fintech issuers carry the credit risk and earn interest, so Mastercard's revenue scales with spending volume rather than lending.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Mastercard Incorporated.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Mastercard Incorporated competitive advantage: Mastercard's advantage is a two-sided network that took decades to build: about 3.7 billion Mastercard and Maestro cards issued by partners and acceptance at tens of millions of merchant locations worldwide. A new rival would need both sides at once. That scale also feeds its fraud models, tokenization service and data products, which makes the services business harder to copy. The limit on the moat is regulation and government-run instant payment systems, not a startup.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Mastercard Incorporated each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Mastercard Incorporated growth strategy: Mastercard's growth plan rests on three levers: moving more consumer spending from cash to cards and tokenized digital wallets, capturing new flows such as B2B payments, disbursements and cross-border remittances, and selling more services that are not tied to card volume. Services grew 23% in FY2025, faster than the network. The company is also extending its multi-rail strategy beyond cards and account-to-account rails into digital assets, closing the BVNK stablecoin infrastructure acquisition in August 2026 and building tools for AI-agent-initiated commerce.

A closer look at the financial trajectory of Amgen Inc. and Mastercard Incorporated rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Mastercard Incorporated: Mastercard's net revenue grew from $10.8 billion in 2016 to $32.8 billion in FY2025, with net income of $14.97 billion in FY2025, a net margin near 46%. Growth continued in 2026: second-quarter net revenue rose 14% to $9.28 billion and net income reached $4.39 billion, with a GAAP operating margin of 60.2%. Because incremental transactions cost little to process, most of that cash goes to share buybacks, dividends and acquisitions such as Recorded Future ($2.65 billion, 2024) and BVNK (up to $1.8 billion, 2026).